within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01M_QuinoloneAntibacterials.J01MA08_Fleroxacin;

model Fleroxacin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.96,
    Cl = 1.7222222222222224e-06,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.085,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.01583333333333333,
    Tlag = 10.200000000000001,
    Vdp = 0.129,
    k12 = 2.722222222222223e-06,
    k21 = 2.722222222222223e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Fleroxacin</td></tr><tr><td>ATC code:</td><td>J01MA08</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>85</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Fleroxacin is a fluoroquinolone antibiotic previously used in the treatment of bacterial infections such as urinary tract infections and respiratory tract infections. It is not widely approved or used today due to safety concerns and the availability of newer fluoroquinolones.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in healthy adult volunteers (both male and female), following single-dose oral administration.</p><h4>References</h4><ol><li><p>Uehlinger, DE, et al., &amp; Frey, FJ (1996). Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. <i>Antimicrobial agents and chemotherapy</i> 40(8) 1903–1909. DOI:<a href=\"https://doi.org/10.1128/AAC.40.8.1903\">10.1128/AAC.40.8.1903</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8843301/\">https://pubmed.ncbi.nlm.nih.gov/8843301</a></p></li><li><p>Schrenzel, J, et al., &amp; Lew, DP (1994). Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. <i>Antimicrobial agents and chemotherapy</i> 38(6) 1219–1224. DOI:<a href=\"https://doi.org/10.1128/AAC.38.6.1219\">10.1128/AAC.38.6.1219</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8092817/\">https://pubmed.ncbi.nlm.nih.gov/8092817</a></p></li><li><p>Jiao, Y, et al., &amp; Bulitta, JB (2018). First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 123 416–428. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2018.07.054\">10.1016/j.ejps.2018.07.054</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30076955/\">https://pubmed.ncbi.nlm.nih.gov/30076955</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01MA08 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Fleroxacin;
